Release 5.9.0: Saved Query Alerts, Query Details, Collection Sizes and more!

Saved Query Alerts.

Receive a notification email when new data is added for your saved queries.

Query Details Improvements.

View details of your joined query when navigating between cited/citing panes.

Collection Limit Increase.

Create collections of up to 50,000 Patents or Scholarly Works.

Use Of Cannabidiol In The Reduction Of Convulsive Seizure Frequency In Treatment-resistant Epilepsy

Full-text?

The full document isn't yet available to us from the patent office, but we've found a related patent (family member) to use for our images and PDF.

Abstract

Cannabidiol (CBD) for use in the treatment of epilepsy where the epilepsy is a treatment-resistant epilepsy (TRE) and where the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 50% with respect to seizure frequency achieved on concomitant anti-epileptic drugs (AED). The TRE may especially be Dravet syndrome, myoclonic absence seizures, or febrile infection related epilepsy syndrome (FIRES). CBD may be administered in combination with two or more concomitant AEDs, especially clobazam, levetiracetam, topiramate, stiripentol, phenobarbital, lacsamide, valproic acid, zonisamide, perampanel, and fosphenytoin. An especially preferred AED is clobazam (Onfi). Preferably the dose of CBD is from 5 mg/kg/day to 25 mg/kg/day.


Claims

Information currently unavailable.

CPC Classifications
Family Member PDF
Family Member Preview
These are the images from a related family member, as the full document isn't yet available to us from the patent office.
Document History
  • Publication: Apr 13, 2016
  • Application: Apr 17, 2015
    GB GB 201506550 A
  • Priority: Jun 17, 2014
    GB GB 201410771 A

Sign in to the Lens